Activ8 Insights
← All reports
AMEX:CITR06/05/2026

Pelican Way Research Short Report on CITR

$6.8
Open on report
$5
Close on report
-26.47%
% since report

Pelican Way Research on CitroTech Inc.


Bottom Line

The allegation. Pelican Way Research alleges that CitroTech is a ~$150mm market-cap promotion built around a commodity food salt (Tri-Potassium Citrate) that has failed to achieve commercial success as a fire retardant across nearly three decades and five prior entities, and is now being marketed to investors by serial promoters with a documented history of failed ventures and associations with censured financial firms.
The company. CitroTech Inc. (NYSE American: CITR) is a Tri-Potassium Citrate-based fire retardant company with approximately $2.4mm in FY25 revenues, trading at a ~$150mm market capitalization, whose core technology traces back to Indonesian inventor Randall Hartolaksono's formulations developed in the 1990s.
The point. With peer-reviewed science showing TPC-based retardants lose effectiveness after water exposure, no verifiable significant commercial relationships, no ISO 9001 certification, management extracting ~$10mm in stock awards on $2.4mm of revenue, and a placement agent (Univest Securities) repeatedly linked to pump-and-dump schemes, Pelican Way believes CitroTech shares are headed materially lower.

Activ8 Report Assessment

Activ8 evaluates every investigator report across three dimensions: the nature of the thesis, the type of evidence supporting it, and the catalyst for stock repricing. Scores are derived solely from the source report. New to these dimensions? Read our guide.

Thesis Classifies the nature of the investigator’s central claim. Structural/Valuation concerns overpricing or business erosion. Governance covers conflicts of interest, self-dealing, or oversight failures. Fraud/Deception involves deliberate misrepresentation, concealment, or securities violations.
Fraud / DeceptionGovernanceStructural / Valuation

Pelican Way alleges deliberate deception including use of a misleading $13.6B TAM figure, over-promotional press releases calling the product 'revolutionary,' and marketing claiming 'weeks to months' of durable protection despite documented water-leaching failures. Governance concerns center on a $7.5mm Conboy royalty clause, ~$10mm in management stock awards on $2.4mm revenue, and insider stock structured to convert and sell into the public market. The stock trades at 57.5x sales on a product the firm believes has no viable commercial path.

Evidence Type Describes the primary type of evidence supporting the thesis. Analytical relies on financial modeling, peer comparisons, or pattern-based inference. Documentary uses SEC filings, court records, or regulatory documents. Primary involves original investigation such as FOIA requests, interviews, site visits, or proprietary research.
AnalyticalDocumentaryPrimary

Pelican Way cites analytical valuation work (57.5x sales multiple, management compensation vs. revenue), documentary evidence including SEC filings (FY25 10-K, patents, EcoBlu SEC records), FINRA censure records for Univest, and peer-reviewed academic research (Yun et al. 2024, University of Göttingen). Primary investigation includes review of patents via Justia, review of the CitroTech website, and field research into predecessor entities and their regulatory histories.

Downside Catalyst Indicates whether a specific event could force the market to reprice the stock. Thesis-Only means no identifiable trigger. Pending Catalyst means a likely catalyst exists without an exact date. Specific Event means a concrete, datable event has been identified.
Thesis-OnlyPending Catalyst

The primary thesis, that a 30-year-old failed chemistry is being promoted at 57.5x sales with no recurring customers, is the core repricing argument. A pending catalyst exists in the form of insider stock conversion and sale mechanics: the retiring of super-voting preferred converted to common with registration rights and a five-day legend strip covenant, which Pelican Way believes is machinery to sell into the public.

Not Present: Specific Event


How CitroTech Makes Money

CitroTech Inc. (NYSE American: CITR) describes itself as an 'environmentally sustainable specialty chemical company focused on fire inhibitor products.' Its fire retardant products are based on Tri-Potassium Citrate (TPC), a commodity food-grade potassium salt whose primary commercial uses are sports drinks, pharmaceuticals, and food processing. The company reported approximately $2.4mm in FY25 revenues per its 10-K and carries a ~$150mm market capitalization. Its products are reportedly blended at a 10,000-square-foot warehouse in Oceanside, CA. The company's FY25 10-K states it 'does not have major sales from recurring customers.' CitroTech's core chemistry originates from formulations developed by Indonesian inventor Randall Hartolaksono in the 1990s.


Main Report Evidence

Insiders Extract Millions While Business Receives Almost Nothing

Pelican Way's analysis of the FY25 10-K shows management received approximately $10mm in stock awards in FY25 alone, roughly 7% of total market capitalization as of May 29, 2026, against only ~$2.4mm in annual revenue. When Craig Huff's ~$5.7mm in stock awards paid to BoltRock Holdings LLC during 2025 is included, total insider extraction balloons to over $15mm. Capital actually invested in the business (R&D, capex in property and equipment, and acquired cash from loan financing) is shown to be a fraction of that extraction.

Insider Extraction vs. Capital Invested in Business — FY25

Item Amount
Management stock awards (named executives)~$10mm
Craig Huff stock awards (to BoltRock Holdings LLC)~$5.7mm
Total insider extraction (including Craig Huff)>$15mm
FY25 Total Revenue~$2.4mm
Management stock awards as % of market cap (as of 5/29/26)~7%

Source: CitroTech FY25 10-K (Page 48 for Craig Huff / BoltRock Holdings disclosure)


Key Allegations

01

TPC Loses Effectiveness After Rain Exposure

A 2024 peer-reviewed study by Sanghun Yun, Adele Chabert, and Holger Militz at the University of Göttingen tested TPC-treated Scots pine at concentrations of 10%, 20%, and 30% via vacuum and impregnation, evaluating fire performance before and after the EN 84:2020 leaching procedure. The study concluded: 'While TPC exhibited high flame retardancy prior to leaching, its efficacy diminished post-leaching, underscoring challenges in fixation and the need for improved retention strategies.' Cone calorimetry, a more rigorous quantitative test than the Bunsen burner test, 'showed less favorable outcomes' on leached specimens. Pelican Way notes that CitroTech's own product-page marketing claims a durable layer lasting 'weeks to months,' and that no rain-resistance test was found in any CitroTech SEC filing or on their website.

02

Same Failed Chemistry, Five Prior Entities

Pelican Way found evidence that the underlying TPC-based chemistry was developed by Indonesian inventor Randall Hartolaksono in the 1990s and marketed through Newstar Chemicals in Malaysia without lasting success. Five separate entities have attempted to commercialize the identical chemistry in North America: Megola Inc. (executed a technology purchase agreement in 2007 with Hartolaksono's Newstar Chemicals, claimed to blend AF21 from 2008, was subsequently sued by Hartolaksono, and is now effectively defunct); EcoBlu Products (OTCBB, led by Steve Conboy, eventually merged into Eco Building Products and had its registration revoked for failure to file); M-Fire Suppression Inc. (a third Conboy-led venture per his LinkedIn); Mighty Fire Holdings LLC (received IP from M-Fire Suppression); and the current CitroTech iteration (GEVI/CITR, received IP from Mighty Fire Holdings). Pelican Way states it could not find a single instance where this technology worked out for investors, and that none have ever generated meaningful revenue. A patent uncovered by Pelican Way further states that a predecessor EcoBlu product was 'produced using… Hartindo AF21 total fire inhibitor' and that 'it was later discovered that these chemical components interacted chemically in an undesired manner, to significantly reduce the fire-inhibiting performance of Hartindo AF21.'

03

No Exclusivity, No ISO Certification, No Recurring Customers

Pelican Way found that CitroTech holds no commercial exclusivity rights to its base chemicals, corroborated by the FY25 10-K statement: 'There are no contracts in place with the suppliers.' Randall Hartolaksono's independent US entity, M-Fire Technologies, markets the same base chemistry under different branding for industrial and structural fire protection applications, and Pelican Way found no acknowledgement of this entity in any CitroTech SEC filing. The company also lacks ISO 9001 certification, the recognized standard for quality management systems. On the customer side, the FY25 10-K states the company 'does not have major sales from recurring customers,' and accounts receivable concentration from three customers stood at ~61.1% at year-end 2025 (down from ~86.3% in 2024), which Pelican Way reads as a small number of one-off municipal and commercial buyers rather than a diversified or recurring revenue stream.

04

Univest Securities: Placement Agent Tied to Pump-and-Dumps

Pelican Way found that Univest Securities LLC has served as sole placement agent for nearly every CitroTech capital raise. Univest was previously censured and fined approximately $20,000 by FINRA for failing to develop an AML program reasonably designed for BSA compliance, involving approximately $37mm in proceeds from foreign clients liquidating low-priced securities. Univest's clearing firm, Velox Clearing, was subject to an SEC Cease-and-Desist for willful Exchange Act violations including failing to file at least 218 SARs, and was fined and censured by FINRA for an inadequate AML program and for not preserving over 10,000 WeChat messages. Among Univest's prior clients: Ostin Technology Group (whose co-CEO was indicted in connection with a $100mm securities fraud pump-and-dump scheme); Faraday Future Intelligent Electric (covered by Wolfpack Research, with shares down ~86% since that September 2025 report; Univest did $175mm+ in placements for FFAI); Super X AI / SUPX (covered by Pelican Way in September 2025 for allegedly fabricating products and being a 'China Hustle,' shares down ~80%+ since that report); and Ebang / EBON (covered by Hindenburg Research, with Univest working with EBON after the Hindenburg report was published).

05

Extreme Overcompensation and Insider-Exit Governance Structure

In FY25, Pelican Way calculated that the named management team received approximately $10mm in stock awards combined, equal to roughly 7% of total market capitalization as of May 29, 2026, against only ~$2.4mm in annual revenue. Craig Huff received an additional ~$5.7mm in stock awards paid to BoltRock Holdings LLC during 2025, bringing total insider extraction to over $15mm. Former CTO Steve Conboy's transition advisory agreement includes a $7.5mm royalty payable in $1.5mm-per-year annual tranches of restricted common stock, triggered only if CitroTech hits $10mm in revenues; Pelican Way notes that even if CitroTech were to quadruple revenue to that threshold, the stock would still trade at ~13.8x sales at current prices, meaning common holders capture zero multiple expansion for hitting the milestone while Conboy begins receiving $1.5mm per year in stock. Separately, Pelican Way found that Chairman Ted Ralston settled a lawsuit by handing over stock he marked at $0.28 per share, versus the ~$6.87 closing price on June 3, 2026, and that the retirement of super-voting preferred stock, framed as a governance cleanup, resulted in insiders swapping into common stock carrying registration rights and a five-day legend strip covenant, which Pelican Way believes is 'the machinery to sell into the public, and NOT a governance reform.'


Disclaimer

The information provided on Activ8Insights.com—including all articles, reports, commentary, and associated content—is intended solely for informational and educational purposes. It does not constitute investment advice, an offer, or a recommendation to buy or sell any securities. All views and opinions presented aim to promote transparency and critical dialogue around activist investing—particularly short activism—and should not be interpreted as personalized financial advice. Investors are solely responsible for their own due diligence and investment decisions, based on publicly available information and their individual financial circumstances. Contributors to or affiliates of Activ8Insights may hold long or short positions in the securities mentioned. These positions may change at any time without notice, and there is no obligation to disclose such changes after publication. Any market data listed is data at the most recent market close. Market data may be delayed or changed after publication on Activ8Insights.com.